Analysis Version
v1
History
Back to Study: Long-term kidney outcomes of semaglutide in obesit...
quantitative
Analysis v1
Strong Support

For adults who are overweight, have heart disease, and early kidney problems but not diabetes, taking a weekly semaglutide shot might help their kidneys work better over two years compared to a placebo.

73
Pro
0
Against

Evidence from Studies

Supporting (1)

73

Community contributions welcome

73

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Randomized Controlled Trial
Human
2024 Jul

The study found that people with early kidney issues who took semaglutide had their kidney function improve more than those who took a placebo, just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Score: 73
DOI: 10.1038/s41591-024-03015-5

Similar Assertions

For adults who are overweight, have heart disease, but don’t have diabetes, taking a weekly semaglutide shot might help slow down how fast their kidneys lose function each year.

73
0
87%

The kidney benefits from taking a weekly semaglutide shot for weight and heart health probably aren't just because it lowers blood sugar or blood pressure — there might be other ways it's helping the kidneys.

73
0
87%

For people with type 2 diabetes and kidney problems, taking a weekly semaglutide shot might help slow down how fast their kidneys get worse.

82
0
86%

Taking a weekly semaglutide shot might help protect the kidneys in people with extra weight and heart disease—even if they don’t have diabetes.

73
0
86%

For adults with type 2 diabetes and kidney problems, taking a weekly semaglutide shot (1.0 mg) can lower their chances of serious kidney or heart issues by about a quarter over 3.4 years — about 1 in every 20 people who take it will avoid a major problem.

82
0
80%